These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 18580541

  • 1. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.
    Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein Fn, Heiman JR, Henderson VW, Hodis HN, Karas RH, Lobo RA, Manson JE, Reid RL, Schmidt PJ, Stuenkel CA, North American Menopause Society.
    Menopause; 2008; 15(4 Pt 1):584-602. PubMed ID: 18580541
    [Abstract] [Full Text] [Related]

  • 2. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2010 Mar; 17(2):242-55. PubMed ID: 20154637
    [Abstract] [Full Text] [Related]

  • 3. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society.
    North American Menopause SocietyNAMS, Cleveland, OH 44101, USA. info@menopause.org.
    Menopause; 2007 Mar; 14(2):168-82. PubMed ID: 17259911
    [Abstract] [Full Text] [Related]

  • 4. The 2017 hormone therapy position statement of The North American Menopause Society.
    Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
    [Abstract] [Full Text] [Related]

  • 5. The 2017 hormone therapy position statement of The North American Menopause Society.
    The NAMS 2017 Hormone Therapy Position Statement Advisory Panel.
    Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
    [Abstract] [Full Text] [Related]

  • 6. The 2012 hormone therapy position statement of: The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2012 Mar; 19(3):257-71. PubMed ID: 22367731
    [Abstract] [Full Text] [Related]

  • 7. The 2022 hormone therapy position statement of The North American Menopause Society.
    “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel.
    Menopause; 2022 Jul 01; 29(7):767-794. PubMed ID: 35797481
    [Abstract] [Full Text] [Related]

  • 8. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.
    Menopause; 2021 Sep 01; 28(9):973-997. PubMed ID: 34448749
    [Abstract] [Full Text] [Related]

  • 9. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010 Sep 01; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [Abstract] [Full Text] [Related]

  • 10. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
    Menopause; 2013 Sep 01; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
    [Abstract] [Full Text] [Related]

  • 11. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2006 Sep 01; 13(3):340-67; quiz 368-9. PubMed ID: 16735931
    [Abstract] [Full Text] [Related]

  • 12. The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society.
    North American Menopause Society.
    Menopause; 2006 Sep 01; 13(6):862-77; quiz 878-80. PubMed ID: 17106282
    [Abstract] [Full Text] [Related]

  • 13. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2003 Sep 01; 10(2):113-32. PubMed ID: 12627037
    [Abstract] [Full Text] [Related]

  • 14. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
    The NAMS 2020 GSM Position Statement Editorial Panel.
    Menopause; 2020 Sep 01; 27(9):976-992. PubMed ID: 32852449
    [Abstract] [Full Text] [Related]

  • 15. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2007 Sep 01; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [Abstract] [Full Text] [Related]

  • 16. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2005 Sep 01; 12(5):496-511; quiz 649. PubMed ID: 16145303
    [Abstract] [Full Text] [Related]

  • 17. Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy.
    Gass M.
    Cleve Clin J Med; 2008 May 01; 75 Suppl 4():S13-6. PubMed ID: 18693638
    [Abstract] [Full Text] [Related]

  • 18. The role of calcium in peri- and postmenopausal women: consensus opinion of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2001 May 01; 8(2):84-95. PubMed ID: 11256879
    [Abstract] [Full Text] [Related]

  • 19. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2004 May 01; 11(1):11-33. PubMed ID: 14716179
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.